Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung

Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung (The PRACTICAL Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07202260

Acronym

PRACTICAL

Enrollment

Registered

2025-10-01

Start date

2025-07-03

Completion date

2028-12-01

Last updated

2025-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer (NSCLC), Lung Cancer (SCLC)

Keywords

radiotherapy, interstitial lung disease, vascular invasion, re-irradiation, rare histology

Brief summary

This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.

Detailed description

By studying detailed patient data, researchers aim to find the best ways to treat these patients while reducing short- and long-term side effects. The findings will help refine radiotherapy treatments, ensuring they are as safe and effective as possible. Additionally, the results will provide doctors with better information to help patients understand the potential risks and benefits of their treatment options.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Complex patients with lung cancer undergoing radiotherapy in one of the following groups; * Rare histology * Disease invading vascular structures * Co-existing interstitial lung disease (ILD) * Radical re-irradiation * Oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.

Exclusion criteria

* Include patients with stage IV disease who are receiving non-curative intent radiotherapy * There are no

Design outcomes

Primary

Measure	Time frame	Description
Acute and late toxicity	2 years	\- Acute (\<90 days post radiotherapy) and late (\> 90 days post radiotherapy) toxicity according to common terminology criteria for adverse events (CTCAE) V5.

Other

Measure	Time frame	Description
Patient reported quality of life	2 years	\- Patient reported quality of life (QOL) information from electronic patient reported outcome measure (ePROM) questionnaires.
Survival	2 years	\- Progression-free survival and overall survival.

Countries

United Kingdom

Outcome results